METHOD FOR PRODUCING A SORBENT USING MULTI-WALLED CARBON NANOTUBES IMMOBILISED ON THE SOLID PHASE OF KSK-2M SILICA GEL AND APPLICATION THEREOF AS AN ACTIVATOR OF BLOOD CELL ELEMENTS IN CONTACT INTERACTION Russian patent published in 2022 - IPC A61M1/34 B01J20/10 B01J20/20 B01J20/32 B01J20/28 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely, to a method for producing a sorbent using multi-walled carbon nanotubes immobilised on the solid phase of KSK-2m silica gel, characterised preliminarily applying cobalt ions to the surface of KSK-2m silica gel by means of ion exchange; wherein said ions are produced from a solution containing: 1 g CoCl₂, 0,66 g NH₄Cl, and 50 cm³ distilled water, whereto drops of ammonia are additionally added until a pH of 8.1, then 2.2 g KSK-2m silica gel is added, and the mixture is stirred for 20 minutes using a magnetic stirrer; the resulting deposited placed on a porous filter is washed and dried for 2 hours at 80°C, then carbon nanotubes are synthesised on the surface of the resulting catalyst by means of chemical vapor deposition (CVD) in a vertical quartz reactor in a fluidised bed mode, wherein ethanol is used as a carbon source; the reactor is then blown with hydrogen for 10 min at a rate providing the fluidised bed mode, the reactor is heated to 600°C, and cobalt is reduced with hydrogen to a metal at the same temperature for 30 minutes, followed by treating the catalyst with ethyl alcohol vapours at 600°C for 30 minutes; inventions also relate to an application of the sorbent using multi-walled carbon nanotubes immobilised on the solid phase of KSK-2m silica gel as contact haemoactivator of blood cell components, providing the possibility of changing the effector-regulator potential thereof in order to effectively treat patients with various diseases by the low-volume haemoperfusion method.

EFFECT: creation of a method for producing a sorbent using multi-walled carbon nanotubes (MWCNT) immobilised on the solid phase of KSK-2m silica gel, and application thereof as a contact haemoactivator of blood cell components, provides the possibility of improve the properties of haemocompatibility of the blood-contacting agent, increasing the effectiveness thereof, and expanding the range of haemocontact agents used in low-volume haemoperfusion.

2 cl, 6 dwg, 4 ex